T-cell epitope discovery for therapeutic cancer vaccines

Sri Krishna, Karen Anderson

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

The success of recent immune checkpoint blockade trials in solid tumors has demonstrated the tremendous potential of immune-mediated treatment strategies for cancer therapy. These immune therapies activate preexisting cytotoxic CD8+ T cells (CTL) to selectively target and eradicate malignant cells. In vitro models suggest that these therapies may be more effective in combination with priming of CTL using cancer vaccines. CTL-mediated tumor targeting is achieved by its recognition of tumor antigenic epitopes presented on human leukocyte antigen (HLA) class I molecules by tumor cells. Discovering CTL-antigenic epitopes is therefore central to the design of therapeutic T-cell vaccines and immune monitoring of these complex immunotherapies. However, selecting and monitoring T-cell epitopes remains difficult due to the extensive polymorphism of HLA alleles and the presence of confounding non-immunogenic self-peptides. To overcome these challenges, this chapter presents methodologies for the design of CTL-targeted vaccines using selection of target HLA alleles, novel integrated computational strategies to predict HLA-class I CTL epitopes, and epitope validation methods using short-term ex vivo T-cell stimulation. This strategy results in the improved efficiency for selecting antigenic epitopes for CTL-mediated vaccines and for immune monitoring of tumor antigens.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages779-796
Number of pages18
Volume1403
DOIs
StatePublished - Apr 1 2016

Publication series

NameMethods in Molecular Biology
Volume1403
ISSN (Print)10643745

Fingerprint

Cancer Vaccines
T-Lymphocyte Epitopes
HLA Antigens
T-Lymphocytes
Immunologic Monitoring
Vaccines
Neoplasms
Epitopes
Therapeutics
Alleles
Neoplasm Antigens
Antigen-Antibody Complex
Immunotherapy
Peptides

Keywords

  • Cytotoxic CD8 T cells
  • HLA typing
  • T-cell epitope

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Krishna, S., & Anderson, K. (2016). T-cell epitope discovery for therapeutic cancer vaccines. In Methods in Molecular Biology (Vol. 1403, pp. 779-796). (Methods in Molecular Biology; Vol. 1403). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3387-7_45

T-cell epitope discovery for therapeutic cancer vaccines. / Krishna, Sri; Anderson, Karen.

Methods in Molecular Biology. Vol. 1403 Humana Press Inc., 2016. p. 779-796 (Methods in Molecular Biology; Vol. 1403).

Research output: Chapter in Book/Report/Conference proceedingChapter

Krishna, S & Anderson, K 2016, T-cell epitope discovery for therapeutic cancer vaccines. in Methods in Molecular Biology. vol. 1403, Methods in Molecular Biology, vol. 1403, Humana Press Inc., pp. 779-796. https://doi.org/10.1007/978-1-4939-3387-7_45
Krishna S, Anderson K. T-cell epitope discovery for therapeutic cancer vaccines. In Methods in Molecular Biology. Vol. 1403. Humana Press Inc. 2016. p. 779-796. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3387-7_45
Krishna, Sri ; Anderson, Karen. / T-cell epitope discovery for therapeutic cancer vaccines. Methods in Molecular Biology. Vol. 1403 Humana Press Inc., 2016. pp. 779-796 (Methods in Molecular Biology).
@inbook{25e6f59a82bf4ba9af55c02e55375792,
title = "T-cell epitope discovery for therapeutic cancer vaccines",
abstract = "The success of recent immune checkpoint blockade trials in solid tumors has demonstrated the tremendous potential of immune-mediated treatment strategies for cancer therapy. These immune therapies activate preexisting cytotoxic CD8+ T cells (CTL) to selectively target and eradicate malignant cells. In vitro models suggest that these therapies may be more effective in combination with priming of CTL using cancer vaccines. CTL-mediated tumor targeting is achieved by its recognition of tumor antigenic epitopes presented on human leukocyte antigen (HLA) class I molecules by tumor cells. Discovering CTL-antigenic epitopes is therefore central to the design of therapeutic T-cell vaccines and immune monitoring of these complex immunotherapies. However, selecting and monitoring T-cell epitopes remains difficult due to the extensive polymorphism of HLA alleles and the presence of confounding non-immunogenic self-peptides. To overcome these challenges, this chapter presents methodologies for the design of CTL-targeted vaccines using selection of target HLA alleles, novel integrated computational strategies to predict HLA-class I CTL epitopes, and epitope validation methods using short-term ex vivo T-cell stimulation. This strategy results in the improved efficiency for selecting antigenic epitopes for CTL-mediated vaccines and for immune monitoring of tumor antigens.",
keywords = "Cytotoxic CD8 T cells, HLA typing, T-cell epitope",
author = "Sri Krishna and Karen Anderson",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/978-1-4939-3387-7_45",
language = "English (US)",
volume = "1403",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "779--796",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - T-cell epitope discovery for therapeutic cancer vaccines

AU - Krishna, Sri

AU - Anderson, Karen

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The success of recent immune checkpoint blockade trials in solid tumors has demonstrated the tremendous potential of immune-mediated treatment strategies for cancer therapy. These immune therapies activate preexisting cytotoxic CD8+ T cells (CTL) to selectively target and eradicate malignant cells. In vitro models suggest that these therapies may be more effective in combination with priming of CTL using cancer vaccines. CTL-mediated tumor targeting is achieved by its recognition of tumor antigenic epitopes presented on human leukocyte antigen (HLA) class I molecules by tumor cells. Discovering CTL-antigenic epitopes is therefore central to the design of therapeutic T-cell vaccines and immune monitoring of these complex immunotherapies. However, selecting and monitoring T-cell epitopes remains difficult due to the extensive polymorphism of HLA alleles and the presence of confounding non-immunogenic self-peptides. To overcome these challenges, this chapter presents methodologies for the design of CTL-targeted vaccines using selection of target HLA alleles, novel integrated computational strategies to predict HLA-class I CTL epitopes, and epitope validation methods using short-term ex vivo T-cell stimulation. This strategy results in the improved efficiency for selecting antigenic epitopes for CTL-mediated vaccines and for immune monitoring of tumor antigens.

AB - The success of recent immune checkpoint blockade trials in solid tumors has demonstrated the tremendous potential of immune-mediated treatment strategies for cancer therapy. These immune therapies activate preexisting cytotoxic CD8+ T cells (CTL) to selectively target and eradicate malignant cells. In vitro models suggest that these therapies may be more effective in combination with priming of CTL using cancer vaccines. CTL-mediated tumor targeting is achieved by its recognition of tumor antigenic epitopes presented on human leukocyte antigen (HLA) class I molecules by tumor cells. Discovering CTL-antigenic epitopes is therefore central to the design of therapeutic T-cell vaccines and immune monitoring of these complex immunotherapies. However, selecting and monitoring T-cell epitopes remains difficult due to the extensive polymorphism of HLA alleles and the presence of confounding non-immunogenic self-peptides. To overcome these challenges, this chapter presents methodologies for the design of CTL-targeted vaccines using selection of target HLA alleles, novel integrated computational strategies to predict HLA-class I CTL epitopes, and epitope validation methods using short-term ex vivo T-cell stimulation. This strategy results in the improved efficiency for selecting antigenic epitopes for CTL-mediated vaccines and for immune monitoring of tumor antigens.

KW - Cytotoxic CD8 T cells

KW - HLA typing

KW - T-cell epitope

UR - http://www.scopus.com/inward/record.url?scp=84963930664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963930664&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3387-7_45

DO - 10.1007/978-1-4939-3387-7_45

M3 - Chapter

VL - 1403

T3 - Methods in Molecular Biology

SP - 779

EP - 796

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -